Potential issues associated with the introduction of virtual control groups into non-clinical toxicology studies-Reference-Cited by-同舟云学术

Potential issues associated with the introduction of virtual control groups into non-clinical toxicology studies

Published:2024 Issue:1 Volume:6 Page:1-9
ISSN:2434-4974
Container-title:Translational and Regulatory Sciences
language:en
Short-container-title:

Author:

SATO Gen¹²,NAKAJIMA Mikio¹³,SAKAI Kuniyoshi¹⁴,TOGASHI Yuko¹⁵,YAMAMOTO Masakatsu¹⁶,INOUE Yuki¹⁷,OSHIMA Takeshi¹⁸,SOH Tetsuyoshi¹⁹,WATANABE Mayumi¹¹⁰,MATSUMOTO Izumi¹¹¹,YAMAMOTO Toshinobu¹¹²,TANAHARU Takashi¹¹³,KAWAKAMI Akio¹¹⁴,MOTOYAMA Keiko¹¹⁵,HASHIMOTO Kiyohiro¹¹⁶,SUZUKI Mutsumi¹⁸

Affiliation:

1. Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association (JPMA), 2-3-11 Nihombashi-honcho, Chuo-ku, Tokyo 103-0023, Japan

2. Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan

3. Asahi Kasei Pharma Corporation, 632-1 Mifuku Izunokuni-shi, Shizuoka 410-2321, Japan

4. ASKA Pharmaceutical Co., Ltd., Shonan Health Innovation Park #B31F-1110, 2-26-1 Muraoka-higashi, Fujisawa, Kanagawa 251-8555, Japan

5. EA Pharma Co., Ltd., 1-1 Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, Japan

6. MSD K.K., Urban Ace Kitahama Bldg., 2-3-7 Hiranomachi, Chuo-ku, Osaka-city, Osaka 541-0046, Japan

7. Otsuka Pharmaceutical Co., Ltd., 463-10 Kagasuno, Kawauchi-cho, Tokushima 771-0192, Japan

8. Kyowa Kirin Co., Ltd., 1188, Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731, Japan

9. Shionogi & Co., Ltd., 3-1-1, Futaba-Cho, Toyonaka, Osaka 561-0825, Japan

10. Daiichi Sankyo Co., Ltd., 1-16-13, Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan

11. Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan

12. Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan

13. Bristol-Myers Squibb K.K., Otemachi One tower 1-2-1 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan

14. Merck Biopharma Co., Ltd., Arco Tower 4F, 1-8-1 Shimomeguro, Meguro-ku, Tokyo 153-8926, Japan

15. Janssen Pharmaceutical K.K., 3-5-2 Nishi-kanda, Chiyoda-ku, Tokyo 101-0065, Japan

16. Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan

Publisher

AMED iD3 Catalyst Unit

Link

https://www.jstage.jst.go.jp/article/trs/6/1/6_2023-009/_pdf

Reference36 articles.

1. 1. Gorzalczany, S. B. and Rodriguez Basso, A. G. 2021. Strategies to apply 3Rs in preclinical testing. Pharmacol. Res. Perspect. 9: e00863.

2. 2. Wadman, M. 2023. FDA no longer needs to require animal tests before human drug trials. Science Insider.

3. 3. EU: European Union 2009. Non-human primates in research and safety testing. https://ec.europa.eu/health/scientific_committees/opinions_layman/en/non-human-primates/index.htm [accessed August 23, 2023].

4. 4. Prior, H., Haworth, R., Labram, B., Roberts, R., Wolfreys, A. and Sewell, F. 2020. Justification for species selection for pharmaceutical toxicity studies. Toxicol. Res. (Camb.) 9: 758–770.

5. 5. Monticello, T. M., Jones, T. W., Dambach, D. M., Potter, D. M., Bolt, M. W., Liu, M., Keller, D. A., Hart, T. K. and Kadambi, V. J. 2017. Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: the IQ consortium nonclinical to clinical translational database. Toxicol. Appl. Pharmacol. 334: 100–109.